Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tinlarebant - Belite Bio

Next Previous
Drug Profile

Tinlarebant - Belite Bio

Alternative Names: aka LBS-008; BPN-14967; LBS-008

Latest Information Update: 29 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University
  • Developer Belite Bio
  • Class Eye disorder therapies; Fluorinated hydrocarbons; Ketones; Piperidines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action RBP4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Stargardt disease
  • Phase III Dry macular degeneration

Most Recent Events

  • 22 Apr 2026 Belite expects to complete the new drug application submission in the second quarter of 2026
  • 21 Apr 2026 Preregistration for Stargardt disease (In adults, In adolescents) in USA (PO) - initiated rolling NDA submission
  • 20 Apr 2026 Belite Bio plans a phase III trial for Stargardt disease (In neonates, In infants, In children, In adolescents, In adults, In the elderly, Treatment-experienced) in Belgium, France, Netherlands (PO) in April 2026 (CTIS2025-522460-33-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top